Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Analysts

Posted by Stacy Sanders on Dec 17th, 2025

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) has received a consensus rating of “Buy” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $31.00.

A number of equities analysts have weighed in on the company. Stifel Nicolaus assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 price objective on the stock. Jefferies Financial Group started coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. Morgan Stanley initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price on the stock. Leerink Partners started coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set an “outperform” rating and a $30.00 price target for the company. Finally, Wall Street Zen cut Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd.

View Our Latest Research Report on Maplight Therapeutics

Maplight Therapeutics Stock Performance

Shares of NASDAQ MPLT opened at $20.35 on Wednesday. Maplight Therapeutics has a 12-month low of $12.24 and a 12-month high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.